- Home
- Publications
- Publication Search
- Publication Details
Title
Tivantinib (ARQ197) in hepatocellular carcinoma
Authors
Keywords
-
Journal
Expert Review of Anticancer Therapy
Volume 15, Issue 6, Pages 615-622
Publisher
Informa UK Limited
Online
2015-06-02
DOI
10.1586/14737140.2015.1050383
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Treating advanced hepatocellular carcinoma: How to get out of first gear
- (2014) James J. Harding et al. CANCER
- Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors
- (2014) Igor Puzanov et al. INVESTIGATIONAL NEW DRUGS
- MET and PI3K/mTOR as a Potential Combinatorial Therapeutic Target in Malignant Pleural Mesothelioma
- (2014) Rajani Kanteti et al. PLoS One
- Metabolism and disposition of [14C]tivantinib after oral administration to humans, dogs and rats
- (2014) Takahiro Murai et al. XENOBIOTICA
- Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors
- (2014) Elizabeth Smyth et al. OncoTargets and Therapy
- GSK3 Alpha and Beta Are New Functionally Relevant Targets of Tivantinib in Lung Cancer Cells
- (2013) Lily L. Remsing Rix et al. ACS Chemical Biology
- A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis
- (2013) A Santoro et al. BRITISH JOURNAL OF CANCER
- Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition
- (2013) R. Katayama et al. CANCER RESEARCH
- Gene Expression Profile Identifies Tyrosine Kinase c-Met as a Targetable Mediator of Antiangiogenic Therapy Resistance
- (2013) A. Jahangiri et al. CLINICAL CANCER RESEARCH
- Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET
- (2013) C. Basilico et al. CLINICAL CANCER RESEARCH
- Poster Sessions
- (2013) HEPATOLOGY
- Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer
- (2013) David R. Spigel et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib in Progressive Medullary Thyroid Cancer
- (2013) Rossella Elisei et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy
- (2013) Yu-Yun Shao et al. JOURNAL OF HEPATOLOGY
- Survival after sorafenib: Expect the unexpected
- (2013) Richard S. Finn JOURNAL OF HEPATOLOGY
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2013) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis
- (2012) T. Pressiani et al. ANNALS OF ONCOLOGY
- Targeting the HGF/Met signaling pathway in cancer therapy
- (2012) Fabiola Cecchi et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
- (2012) Armando Santoro et al. LANCET ONCOLOGY
- Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia
- (2012) Annamaria Rapisarda et al. Nature Reviews Clinical Oncology
- c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma
- (2011) Hanning You et al. HEPATOLOGY
- Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies
- (2011) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity
- (2010) N. Munshi et al. MOLECULAR CANCER THERAPEUTICS
- Phosphorylation of focal adhesion kinase on tyrosine 194 by Met leads to its activation through relief of autoinhibition
- (2010) T-H Chen et al. ONCOGENE
- Crosstalk in Met receptor oncogenesis
- (2009) Andrea Z. Lai et al. TRENDS IN CELL BIOLOGY
- Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma
- (2008) Ai-Wu Ke et al. HEPATOLOGY
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started